Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
NASDAQ:HUMA
HUMA Stock Chart & Stats
$1.69
-$0.19(-4.01%)
At close: 4:00 PM EST
$1.69
-$0.19(-4.01%)
Day’s Range― - ―
52-Week Range$1.15 - $6.77
Previous CloseN/A
Volume1.64M
Average Volume (3M)6.40M
Market Cap
$318.36M
Enterprise Value$370.50M
Total Cash (Recent Filing)$38.03M
Total Debt (Recent Filing)$15.12M
Price to Earnings (P/E)―
Beta2.52
Next Earnings
Nov 07, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding187,271,320
10 Day Avg. Volume4,896,455
30 Day Avg. Volume6,404,595
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)-11.36
Price to Sales (P/S)0.00
P/FCF Ratio-6.00
Enterprise Value/Market Cap1.16
Enterprise Value/Revenue46.05
Enterprise Value/Gross Profit865.64
Enterprise Value/Ebitda-9.92
Forecast
1Y Price Target
$6.00Price Target Upside255.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Market ExpansionHUMA's clearance on the Electronic Catalog (ECAT) opens up Symvess to ~190 military facilities where Symvess will have increased utility in vascular trauma.
Product ApprovalSymvess received FDA approval for vascular trauma treatment based on strong trial results, including high patency and zero infection rates after 30 days.
Sales GrowthSymvess adoption picked up considerably during the month of July generating $300K, exceeding 1H25 sales of $247K.
Bears Say
Lowered Revenue ProjectionsConsidering the weak 1H25 sales, the 2025 total revenues have been conservatively lowered to $2.5M from prior $10.4M.
Onboarding DelaysGetting the remainder of the hospitals through the entire process is taking longer than planned, now estimated at 6-9 months (up from 3-6 months).
Revenue ShortfallHumacyte reported 2Q revenue of $0.3 million, below our estimate of $1.0 million and the broader consensus estimate of $0.8 million.
Humacyte News
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $1.15 and its highest was $6.77 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $318.36M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Nov 07, 2025 which is in 8 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on Aug 11, 2025. The company reported -$0.24 earnings per share for the quarter, missing the consensus estimate of -$0.162 by -$0.078.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.15.
How many shares outstanding does Humacyte have?
Humacyte has 187,271,320 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.24 in its last earnings report, missing expectations of -$0.162. Following the earnings report the stock price went down -29.839%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
Humacyte Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (255.03% Upside)
$6.00 (255.03% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 75%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 5.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 5.0%
Last 30 Days ▲ 5.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.37%
Trailing 12-Months
Company Description
Humacyte
Humacyte, Inc. (HUMA) is a biotechnology company focused on developing bioengineered human tissues and organs for use in regenerative medicine and vascular surgery. The company's core product revolves around its proprietary platform technology to create universally implantable, bioengineered human tissues that have the potential to improve treatment outcomes for patients with vascular and organ diseases. Humacyte operates primarily within the healthcare and biotechnology sectors, leveraging its innovative technology to address significant unmet medical needs.
HUMA Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted significant progress in expanding Symvess approvals and sales, including entering military markets, and successful clinical trial results. However, challenges included a denial of CMS NTAP application and delays caused by public attacks.View all HUMA earnings summariesHUMA Stock 12 Month Forecast
Average Price Target
$6.00
▲(255.03% Upside)
Technical Analysis
Cartesian Therapeutics
―
Allogene Therapeutics
―
I-MAB
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
1.63% Insiders
5.65% Mutual Funds
0.04% Other Institutional Investors
85.69% Public Companies and
Individual Investors